Literature DB >> 1381765

Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine.

M A Vos1, A P Gorgels, J D Leunissen, T van der Nagel, F J Halbertsma, H J Wellens.   

Abstract

In conscious dogs with chronic atrioventricular (AV) block, we recently demonstrated that flunarizine is effective against ouabain-induced arrhythmias (triggered activity resulting from delayed afterdepolarizations, DADs) but fails to suppress spontaneous ventricular tachycardias (VT) occurring 24 h after left anterior descending coronary artery occlusion (abnormal automaticity). Neither does flunarizine affect normal automaticity, which suggests that flunarizine could be used as a clinical tool to recognize cardiac arrhythmias based on triggered activity. To elucidate further the arrhythmia mechanism-specific action of flunarizine, we investigated (a) its hemodynamic and electrophysiologic effects in 6 anesthetized dogs, (b) its ability to prevent pacing-induced VT 7 days after myocardial infarction (reentry) in 9 anesthetized animals, and (c) its effect on premature escape beats (PEBs) in 9 conscious dogs with chronic AV block. PEBs are probably caused by DADs. Flunarizine decreased systemic blood pressure (p less than 0.01), and left ventricular dP/dt (p less than 0.01), but did not affect AH or HV internal, QRS duration, QT time, or the effective refractory period of either AV node or right ventricle over a wide range of (paced) cycle lengths. Flunarizine decreased the inducibility of PEBs by 42% (p less than 0.01), but not that of the reentrant VT in any of the 6 inducible dogs. Therefore, we conclude that although flunarizine has no electrophysiologic effects in normal heart, it prevents induction of PEBs. The inability of flunarizine to prevent induction of reentrant VT confirms the mechanism-specific action of flunarizine against triggered activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381765

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

Authors:  A Oros; M J Houtman; P Neco; A M Gomez; S Rajamani; P Oosterhoff; N J Attevelt; J D Beekman; M A G van der Heyden; L Ver Donck; L Belardinelli; S Richard; G Antoons; M A Vos
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

2.  Termination of a tachyarrhythmia by flunarizine is not a specific marker for a triggered mechanism.

Authors:  Sergey A Vitebskiy; Celeen M Khrestian; Albert L Waldo
Journal:  Heart Rhythm       Date:  2007-08-24       Impact factor: 6.343

3.  HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade.

Authors:  Alexei N Plotnikov; Annalisa Bucchi; Iryna Shlapakova; Peter Danilo; Peter R Brink; Richard B Robinson; Ira S Cohen; Michael R Rosen
Journal:  Heart Rhythm       Date:  2007-10-03       Impact factor: 6.343

4.  Long-duration ventricular fibrillation exhibits 2 distinct organized states.

Authors:  Li Li; Xiangsheng Zheng; Derek J Dosdall; Jian Huang; Steven M Pogwizd; Raymond E Ideker
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-11-15

5.  Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype.

Authors:  Fatima Jaffer; Andreja Avbersek; Rosaria Vavassori; Carmen Fons; Jaume Campistol; Michela Stagnaro; Elisa De Grandis; Edvige Veneselli; Hendrik Rosewich; Melania Gianotta; Claudio Zucca; Francesca Ragona; Tiziana Granata; Nardo Nardocci; Mohamed Mikati; Ashley R Helseth; Cyrus Boelman; Berge A Minassian; Sophia Johns; Sarah I Garry; Ingrid E Scheffer; Isabelle Gourfinkel-An; Ines Carrilho; Sarah E Aylett; Matthew Parton; Michael G Hanna; Henry Houlden; Brian Neville; Manju A Kurian; Jan Novy; Josemir W Sander; Pier D Lambiase; Elijah R Behr; Tsveta Schyns; Alexis Arzimanoglou; J Helen Cross; Juan P Kaski; Sanjay M Sisodiya
Journal:  Brain       Date:  2015-08-21       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.